In last trading session, CureVac N.V (NASDAQ:CVAC) saw 0.35 million shares changing hands with its beta currently measuring 2.41. Company’s recent per share price level of $3.23 trading at -$0.03 or -0.92% at ring of the bell on the day assigns it a market valuation of $727.26M. That closing price of CVAC’s stock is at a discount of -63.47% from its 52-week high price of $5.28 and is indicating a premium of 31.58% from its 52-week low price of $2.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 626.37K if we extend that period to 3-months.
For CureVac N.V (CVAC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.14 in the current quarter.
CureVac N.V (NASDAQ:CVAC) trade information
Upright in the red during last session for losing -0.92%, in the last five days CVAC remained trading in the green while hitting it’s week-highest on Friday, 04/25/25 when the stock touched $3.23 price level, adding 4.44% to its value on the day. CureVac N.V’s shares saw a change of -5.28% in year-to-date performance and have moved 3.53% in past 5-day. CureVac N.V (NASDAQ:CVAC) showed a performance of 13.33% in past 30-days. Number of shares sold short was 4.85 million shares which calculate 7.67 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 29 to the stock, which implies a rise of 88.86% to its current value. Analysts have been projecting 21 as a low price target for the stock while placing it at a high target of 37. It follows that stock’s current price would drop -550.15% in reaching the projected high whereas dropping to the targeted low would mean a loss of -550.15% for stock’s current value.
CureVac N.V (CVAC) estimates and forecasts
This year revenue growth is estimated to fall -89.80% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.27M for the same. And 3 analysts are in estimates of company making revenue of 4.27M in the next quarter. Company posted 12.37M and 14.44M of sales in current and next quarters respectively a year earlier.
In 2025, company’s earnings growth rate is likely to be around -173.07% while estimates for its earnings growth in next 5 years are of -28.24%.
CureVac N.V (NASDAQ:CVAC)’s Major holders
Insiders are in possession of 58.37% of company’s total shares while institution are holding 4.65 percent of that, with stock having share float percentage of 11.16%. Investors also watch the number of corporate investors in a company very closely, which is 4.65% institutions for CureVac N.V that are currently holding shares of the company. MILLENNIUM MANAGEMENT LLC is the top institutional holder at CVAC for having 2.87 million shares of worth $9.77 million. And as of 2024-06-30, it was holding 1.2808 of the company’s outstanding shares.
The second largest institutional holder is POINT72 ASSET MANAGEMENT, L.P., which was holding about 2.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.0801 of outstanding shares, having a total worth of $8.24 million.
On the other hand, iShares Trust-iShares Core MSCI EAFE ETF and iShares Trust-iShares Biotechnology ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 652.13 shares of worth $2.11 million or 0.29% of the total outstanding shares. The later fund manager was in possession of 598.13 shares on Mar 31, 2025 , making its stake of worth around $1.93 million in the company or a holder of 0.27% of company’s stock.
